Sage Journals: Discover world-class research

Abstract

Background

With the recent publication of the International Conference on Harmonisation E17 guideline and major reforms in China underway, the platform for clinical trial conduct is expected to change. This study aims to assess the strategic inclusion of regions in clinical trials and its change in trends over the past decade.

Methods

The ClinicalTrials.gov registry was searched for clinical trials registered by the top 10 pharmaceutical companies between 1 January 2008 and 31 December 2017. Extracted data included phase, disease type, intervention, study start year, and region. Trial type was classified as either a local study or a multiregional clinical trial as per the International Conference on Harmonisation E17 guideline.

Results

Of 2488 phase I, 1855 phase II, and 1999 phase III trials included, the majority of phase I trials were local studies (76.8%), while the majority of phase II (66.0%) and phase III (72.2%) trials were multiregional clinical trials. The proportion of multiregional clinical trials showed an increasing trend for all phases (p < 0.01). Although North America and Europe remained the main locations, increasing trends of inclusion of other regions, such as East Asia, were noted.

Conclusion

Globalization of drug development is evident with the increasing trend of multiregional clinical trial. Regulatory authorities as well as the pharmaceutical industry should prepare for the evolving setting of clinical research and problems that can arise from these changes.

Keywords

Multiregional clinical trial region clinical trial

Get full access to this article

View all access options for this article.

References

International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: ethnic factors in the acceptability of foreign clinical data. ICH E5(R1), https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdf

Shenoy

Multi-regional clinical trials and global drug development. Perspect Clin Res 2016; 7(2): 62–67.

Ando

Hamasaki

Practical issues and lessons learned from multi-regional clinical trials via case examples: a Japanese perspective. Pharm Stat 2010; 9(3): 190–200.

Asano

Tanaka

Sato

et al . Regulatory challenges in the review of data from global clinical trials: the PMDA perspective. Clin Pharmacol Ther 2013; 94(2): 195–198.

Ohishi

Potential factors influencing regional differences and similarities in multiregional clinical trials. Drug Inf J 2012; 46: 565–572.

Eichler

H-G

Sweeney

The evolution of clinical trials: can we address the challenges of the future?

Clin Trials 2018; 15(1 Suppl.): 27–32.

Girman

Ibia

Shailendr

et al . Impact of different regulatory requirements for trial endpoints in multiregional clinical trials. Drug Inf J 2011; 45: 587–594.

Carroll

Le Maulf

Japanese guideline on global clinical trials: statistical implications and alternative criteria for assessing consistency. Drug Inf J 2011; 45: 657–667.

Tsou

Tsong

Chang

et al . Design and analysis issues of multiregional clinical trials with different regional primary endpoints. J Biopharm Stat 2012; 22(5): 1051–1059.

10.

Kawai

Chuang-Stein

Komiyama

et al . An approach to rationalize partitioning sample size into individual regions in a multiregional trial. Drug Inf J 2008; 42: 139–147.

11.

International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. ICH harmonised guideline: general principles for planning and design of multi-regional clinical trials. ICH E17, 2017, https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E17/E17EWG_Step4_2017_1116.pdf

12.

Miyazaki

Sato

Hanaoka

et al . Current status and open issues concerning global clinical trials (GCTs) in Japan and East Asia. Clin Transl Sci 2017; 10(6): 503–508.

13.

Kudrin

Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast Asia. J Clin Pharmacol 2009; 49(3): 268–280.

14.

China Food and Drug Administration. Announcement of the general administration of administration on soliciting opinions on the “relevant policies for encouraging pharmaceuticals and medical device innovation through reform of clinical trial management” (Draft for Comment) (No. 53 of 2017). Beijing, China: China Food and Drug Administration, 2017 (in Chinese).

15.

China Food and Drug Administration. Announcement of the general administration of administration of China on soliciting opinions on the “relevant policies for encouraging drugs/medical device innovation to accelerate the review and approval of new medicines and medical devices” (Draft for Comment) (No. 52 of 2017). Beijing, China: China Food and Drug Administration, 2017 (in Chinese).

16.

Battelle Technology Partnership Practice. Biopharmaceutical industry-sponsored clinical trials: impact on state economies, 2015, http://phrma-docs.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-sponsored-clinical-trials-impact-on-state-economies.pdf

17.

Khin

Yang

Hung

et al . Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective. Clin Pharmacol Ther 2013; 94(2): 230–242.

18.

Ministry of Health Labour Welfare. Basic principles on global clinical trials. Ministry of Health Labour Welfare, 2007. https://www.pmda.go.jp/files/000153265.pdf

19.

Ministry of Health Labour Welfare. Basic principles for conducting phase I trials in the Japanese population prior to global clinical trials. Ministry of Health Labour Welfare, 2014. https://www.pmda.go.jp/files/000157777.pdf

20.

Nonaka

. Review experiences of global clinical trials in Japan. Pharmaceuticals and Medical Devices Agency, 2012. https://www.pmda.go.jp/files/000157680.pdf

21.

Shirotani

Kurokawa

Chiba

Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan. J Clin Pharmacol 2014; 54(7): 753–764.

22.

Chen

Zhao

Recent advances in drug development and regulatory science in China. Ther Innov Regul Sci. Epub ahead of print 3 April 2018. DOI: 10.1177/2168479018764661.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.79 MB

Strategic inclusion of regions in multiregional clinical trials